Multiple Myeloma Clinical Trial

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Summary

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Relapsed/Refractory Multiple Myeloma

Confirmed diagnosis and evidence of progressive disease or clinical relapse as defined by International Myeloma Working Group criteria and following prior therapy for multiple myeloma (MM)
Relapsed or refractory MM requiring current treatment
Previously failed ≥ 3 prior regimens (after at least 2 cycles of medication per regimen) and included at least 1 immunomodulatory drug, 1 proteasome inhibitor, and an anti-CD38 antibody agent

Participants must have measurable disease as defined by at least 1 of the following:

Serum M-protein ≥ 0.5 grams/deciliter (dL) by serum protein electrophoresis or for immunoglobulin A (IgA) myeloma, by quantitative IgA; or
Urinary M-protein excretion at least 200 milligrams (mg)/24 hours; or
Serum free light chain whereby the involved light chain measures ≥ 10 mg/dL and with an abnormal ratio
Estimated life expectancy ≥ 3 months
No other medical, surgical, or psychiatric condition (including active substance abuse) that would interfere with compliance to the protocol, as determined by the principal investigator

Key Exclusion Criteria:

Concurrent invasive malignancy
Participants who had an allogeneic stem cell transplantation and are still on immunosuppressive medications or corticosteroids above physiological dose within 4 weeks before agenT-797
Prior radiotherapy within 2 weeks of start of study treatment
Prior systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks prior to dose of study drug

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT04754100

Recruitment Status:

Active, not recruiting

Sponsor:

MiNK Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida
Louisville Kentucky, 40207, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
University of Cincinnati Cancer Center
Cincinnati Ohio, 45267, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT04754100

Recruitment Status:

Active, not recruiting

Sponsor:


MiNK Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.